Adjuvants, Immunologic - Research News and Information

Wednesday, January 07, 2009

Fine ambient particles from various sites in europe exerted a greater IgE adjuvant effect than coarse ambient particles in a mouse model.

30 Dec 2008 In the European Union (EU)-funded project Respiratory Allergy and Inflammation due to Ambient Particles (RAIAP), coarse and fine ambient particulate matter (PM) was collected at traffic dominated locations in Oslo, Rome, Lodz, and Amsterdam, in the ... Read more...

Correlation between direct ELISA, single epitope-based inhibition ELISA and pseudovirion-based neutralization assay for measuring anti-HPV-16 and anti-HPV-18 antibody response after vaccination with the AS04-adjuvanted HPV-16/18 cervical cancer vaccine.

9 Nov 2008 To monitor immune status during clinical trials and after vaccine registration, several assays have been developed to measure type-specific human papillomavirus (HPV) serum antibody levels. These include neutralization assays, single epitope-based ... Read more...

Adjuvants LT-K63 and CpG enhance the activation of dendritic cells in neonatal mice.

30 Oct 2008 Dendritic cells (DC) play a major role in the priming of T cells and initiating specific immune responses. We assessed the effects of the adjuvants LT-K63 and CpG on neonatal DC in vivo and in vitro. Cytokine levels (IL-10, IL-12p70 and ... Read more...

Learn Faster Today      Improve your study skills

Latest indexed articles for 'Adjuvants, Immunologic'

These are the very latest articles for this heading:

• Fine ambient particles from various sites in europe exerted a greater IgE adjuvant effect than coarse ambient particles in a mouse model. 30 Dec 2008
• Correlation between direct ELISA, single epitope-based inhibition ELISA and pseudovirion-based neutralization assay for measuring anti-HPV-16 and anti-HPV-18 antibody response after vaccination with the AS04-adjuvanted HPV-16/18 cervical cancer vaccine. 9 Nov 2008
• Adjuvants LT-K63 and CpG enhance the activation of dendritic cells in neonatal mice. 30 Oct 2008
• Alemtuzumab vs. interferon beta-1a in early multiple sclerosis. 21 Oct 2008
• Multiple lessons for multiple sclerosis. 21 Oct 2008
• Imidazoquinoline acts as immune adjuvant for functional alteration of thymic stromal lymphopoietin-mediated allergic T cell response. 13 Oct 2008
• The indoleamine 2,3-dioxygenase pathway is essential for human plasmacytoid dendritic cell-induced adaptive T regulatory cell generation. 13 Oct 2008
• Glucocorticoid-induced TNF receptor expression by T cells is reciprocally regulated by NF-kappaB and NFAT. 13 Oct 2008
• B cells from patients with Graves' disease aberrantly express the IGF-1 receptor: implications for disease pathogenesis. 13 Oct 2008
• Effect of CpG oligonucleotides on vaccine-induced B cell memory. 13 Oct 2008
• Antigenically distinct MF59-adjuvanted vaccine to boost immunity to H5N1. 7 Oct 2008
• Vaccines against pandemic influenza: what can be done before the next pandemic? 29 Sep 2008
• Diamyd, an alum-formulated recombinant human GAD65 for the prevention of autoimmune diabetes. 29 Sep 2008
• 4th International Workshop in Vaccine Adjuvants and Parasitic Vaccines (adjuvant 2008). 29 Sep 2008
• Heat-shock proteins as powerful weapons in vaccine development. 29 Sep 2008
• [Nasal vaccines] 29 Sep 2008
• [Innovation of vaccine adjuvants] 29 Sep 2008
• An intranasal heat shock protein based vaccination strategy confers protection against mucosal challenge with herpes simplex virus. 26 Sep 2008
• [Registration of the first human vaccine against the highly pathogenic avian influenza A(H5N1) virus: considerations] 25 Sep 2008
• Synergistic immunostimulating activity of pidotimod and red ginseng acidic polysaccharide against cyclophosphamide-induced immunosuppression. 18 Sep 2008

See a longer list of these articles.

Technical information about 'Adjuvants, Immunologic'

Definition: Substances that augment, stimulate, activate, potentiate, or modulate the immune response at either the cellular or humoral level. The classical agents (Freund's adjuvant, BCG, Corynebacterium parvum, et al.) contain bacterial antigens. Some are endogenous (e.g., histamine, interferon, transfer factor, tuftsin, interleukin-1). Their mode of action is either non-specific, resulting in increased immune responsiveness to a wide variety of antigens, or antigen-specific, i.e., affecting a restricted type of immune response to a narrow group of antigens. The therapeutic efficacy of many biological response modifiers is related to their antigen-specific immunoadjuvanticity.

Registry Number: 0

Descriptor UI: D000276

Alternative terms: Adjuvants, Immunologic; Adjuvants, Immunological; Immunological Adjuvants; Immunological Adjuvant; Adjuvant, Immunological; Adjuvant, Immunologic; Immunologic Adjuvant; Immunopotentiators; Immunoactivators; Immunoadjuvants; Immunostimulants; Immunologic Adjuvants;

Related Mesh Headings: Adjuvants, Pharmaceutic;

Allowable Qualifiers: administration & dosage; adverse effects; analysis; antagonists & inhibitors; biosynthesis; blood; cerebrospinal fluid; chemical synthesis; classification; deficiency; diagnostic use; economics; genetics; history; isolation & purification; metabolism; pharmacokinetics; pharmacology; physiology; poisoning; radiation effects; secretion; standards; supply & distribution; therapeutic use; toxicity; urine; chemistry; contraindications; agonists;

Tree Number: D27.505.696.477.067;

History Note: 65

Technical Notes: DF: ADJUVANTS IMMUNOL